BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships

Rhea-AI Summary

BioMark Diagnostics (OTCQB: BMKDF), a liquid biopsy test developer, has completed a strategic laboratory equipment leasing agreement that doubles its testing capacity in Quebec. This expansion supports the upcoming commercial launch of its metabolomic-based lung cancer diagnostic assay and enhances the company's ability to provide advanced diagnostic analytical molecular services.

The upgraded facility will serve as a certified and accredited laboratory, enabling broad deployment through clinical partnerships, centralized testing services, and expanded contract research programs. The expansion positions BioMark to meet increasing global demand for non-invasive liquid biopsy diagnostics and supports research collaborations with healthcare institutions and pharmaceutical companies.

Positive

• Strategic equipment leasing agreement doubles testing capacity
• Positions for commercial launch of lung cancer diagnostic assay
• Expands capabilities for international pharmaceutical and biotech partnerships
• Enhanced platform for clinical validation studies and regulatory filings
• Facilitates deployment of multiple new assays

Negative

• Laboratory certification and accreditation still pending
• Significant operational costs from equipment leasing agreement

Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for the imminent commercial launch of its lung cancer assay. This critical advancement in its operational capabilities solidifies the expansion of its diagnostic and research services and positions the Company as a central hub for innovation, high-throughput diagnostics, and collaborative ventures.

Accelerating Commercialization and Market Entry for Life-Saving Diagnostics
The newly acquired state-of-the-art laboratory equipment is aligned with BioMark's commercialization strategy. This enhanced capacity directly addresses the escalating global demand for non-invasive liquid biopsy diagnostics and, crucially, prepares the Company for the widespread clinical deployment of its metabolomic-based lung cancer diagnostic assay. The expansion also facilitates the provision of advanced diagnostic analytical molecular services to international clients and significantly expands its research capabilities to accommodate the growing needs of metabolomics from pharmaceutical and biotechnology companies. Furthermore, this initiative supports the accelerated rollout of multiple new assays, aligning with the company's laboratory certification and accreditation roadmap.

"Our enhanced laboratory capacity underscores BioMark's unwavering commitment to clinical excellence, innovation, and accessibility," stated Jean-Francois Haince, CSO and GM of BioMark Diagnostic Solutions. "Once certified, this laboratory will serve as a pivotal engine for commercialization, revenue generation, strategic partnerships, and the widespread clinical deployment of our metabolomic-based diagnostic assays."

Creating a Platform for Scalable Growth and Strategic Value
This strategic laboratory upgrade aligns with BioMark's vision to establish an agile, clinically robust platform capable of supporting research on advanced cancer. It will also facilitate ongoing clinical research collaborations with global healthcare institutions and pharmaceutical companies, while streamlining regulatory filings and clinical validation studies for new indications and expansion into international markets. BioMark's forthcoming certified and accredited laboratory will be instrumental in enabling a broad deployment strategy through robust clinical partnerships, centralized testing services, and expanded contract research programs.

"Our team remains intensely focused on achieving key milestones and enhancing long-term shareholder value," added Rashid Ahmed Bux, President & CEO of BioMark. "This accomplishment strategically positions BioMark at a significant advantage within the diagnostic arena, marking a critical enabler as we continue to scale our AI-enhanced assays and foster collaborations across the entire cancer care spectrum. We are now well-equipped to meet the anticipated demand for our innovative solutions and drive significant growth."

About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved of the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261250

FAQ

What is the significance of BioMark's (BMKDF) laboratory expansion in Quebec?

The expansion doubles BioMark's testing capacity and positions the company for the commercial launch of its lung cancer assay, while enabling advanced diagnostic services for international clients.

How will the new laboratory equipment affect BioMark's (BMKDF) operations?

The equipment will enable high-throughput diagnostics, support clinical partnerships, facilitate regulatory filings, and expand contract research capabilities for pharmaceutical collaborations.

What are the main benefits of BioMark's (BMKDF) laboratory expansion for cancer diagnostics?

The expansion enables non-invasive liquid biopsy diagnostics, metabolomic-based lung cancer testing, and supports research on advanced cancer through global healthcare institution partnerships.

When will BioMark's (BMKDF) expanded laboratory be fully operational?

The laboratory is awaiting certification and accreditation before becoming fully operational for commercial deployment of diagnostic assays.

How does the laboratory expansion align with BioMark's (BMKDF) growth strategy?

The expansion supports BioMark's strategy for commercialization, revenue generation, and strategic partnerships while enabling broad deployment through clinical partnerships and centralized testing services.